Normal IDH1SNP (N = 69, 86.2%) | Heterozygous IDH1SNP mutation (N = 11, 13.8%) | p value*# | ||
---|---|---|---|---|
Age (years) | Mean ± SD | 42.1 ± 14.2 | 62.3 ± 15.7 | < 0.001 |
Gender | N (%) | |||
Male | 50 (72.5) | 6 (54.5) | 0.228 | |
Female | 19 (27.5) | 5 (45.5) | ||
Hepatomegaly | N (%) | |||
Negative | 36 (52.2) | 7 (63.6) | 0.479 | |
Positive | 33 (47.8) | 4 (36.4) | ||
Splenomegaly | N (%) | |||
Negative | 23 (33.3) | 6 (54.5) | 0.174 | |
Positive | 46 (66.7) | 5 (45.5) | ||
Lymphadenopathy | N (%) | |||
Negative | 44 (63.8) | 10 (90.9) | 0.074 | |
Positive | 25 (36.2) | 1 (9.1) | ||
Hemoglobin (g/dl) | Mean ± SD | 6.7 ± 1.7 | 7.3 ± 1.0 | 0.260 |
TLC (× 109/L) | Mean ± SD | 68.4 ± 39 | 72.7 ± 58.7 | 0.754 |
Platelets (× 109/L) | Mean ± SD | 26.6 ± 16.2 | 48.1 ± 9.2 | < 0.001 |
Blast cells (%) | Mean ± SD | 69.6 ± 16.1 | 87.8 ± 6.3 | < 0.001 |
FAB classification | N (%) | 0.099 | ||
M1 | 10 (14.5) | 4 (36.4) | ||
M2 | 37 (53.6) | 7 (63.6) | ||
M4 | 16 (23.2) | 0 (0) | ||
M5 | 6 (8.7) | 0 (0) | ||
IDH2R140Q | N (%) | 0.488 | ||
Normal | 57 (82.6) | 10 (90.9) | ||
Heterozygous | 12 (17.4) | 1 (9.1) | ||
Outcome at 28 days | N (%) | 0.054 | ||
Favorable+ | 18 (26.1) | 0 (0) | ||
Unfavorable++ | 51 (73.9) | 11 (100) | ||
Outcome at 6 months | N (%) | 0.003 | ||
Favorable+ | 33 (47.8) | 0 (0) | ||
Unfavorable+++ | 36 (52.2) | 11(100) | ||
Median survival (days) | Median (IQR) | 170 (27–170) | 12 (8–20) | < 0.0001 |